Literature DB >> 11228213

Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol.

F J Roumen1, D Apter, T M Mulders, T O Dieben.   

Abstract

A novel contraceptive vaginal ring releasing etonogestrel 120 microg and ethinyl oestradiol 15 microg daily over a period of 3 weeks was tested. Each ring was used for one cycle, comprising 3 weeks of ring use followed by a 1 week ring-free period. This 1 year, multicentre study assessed the contraceptive efficacy, cycle control, tolerability and acceptability of the contraceptive. Altogether, 1145 women were exposed to the vaginal ring for 12,109 cycles (928 woman-years). Six pregnancies occurred during treatment, giving a Pearl Index of 0.65 (95% confidence interval 0.24--1.41). Cycle control was very good, since irregular bleeding was rare (2.6--6.4% of evaluable cycles) and withdrawal bleeding (mean duration 4.7--5.3 days) occurred in 97.9--99.4% of evaluable cycles. Compliance to the prescribed regimen was high with criteria being fulfilled in 90.8% of cycles. The ring was well tolerated. The majority of women considered this new contraceptive method easy to use, and it offers an effective, convenient, well-accepted and novel method for hormonal contraception.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11228213     DOI: 10.1093/humrep/16.3.469

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  31 in total

Review 1.  Recent developments in hormonal contraception.

Authors:  Eleanor A Drey; Philip D Darney
Journal:  Rev Endocr Metab Disord       Date:  2002-09       Impact factor: 6.514

2.  Development and validation of an acceptability and satisfaction questionnaire for a contraceptive vaginal ring, NuvaRing.

Authors:  Annoesjka Novák; Christine de la Loge; Linda Abetz
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

3.  Absence of pharmacokinetic interactions of the combined contraceptive vaginal ring NuvaRing with oral amoxicillin or doxycycline in two randomised trials.

Authors:  Peter Dogterom; Michiel W van den Heuvel; Torben Thomsen
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 4.  Development of topical microbicides to prevent the sexual transmission of HIV.

Authors:  Robert W Buckheit; Karen M Watson; Kathleen M Morrow; Anthony S Ham
Journal:  Antiviral Res       Date:  2009-10-27       Impact factor: 5.970

Review 5.  Effect of missed combined hormonal contraceptives on contraceptive effectiveness: a systematic review.

Authors:  Lauren B Zapata; Maria W Steenland; Dalia Brahmi; Polly A Marchbanks; Kathryn M Curtis
Journal:  Contraception       Date:  2012-10-22       Impact factor: 3.375

6.  Efficacy, user acceptability, tolerability, and cycle control of a combined contraceptive vaginal ring: the Indian perspective.

Authors:  Anita Soni; Seeru Garg; Rani Bangar
Journal:  J Obstet Gynaecol India       Date:  2013-05-01

7.  Multicenter Study of Contraceptive Vaginal Ring (NuvaRing(®)) in Normal Daily Practice in Indian Women.

Authors:  Suchitra N Pandit; Anahita R Chauhan; Manjula Anagani; Sanjeeva Reddy; Ashish Birla; Subrat K Ray
Journal:  J Obstet Gynaecol India       Date:  2014-05-15

8.  Female genital tract secretions inhibit herpes simplex virus infection: correlation with soluble mucosal immune mediators and impact of hormonal contraception.

Authors:  Gail F Shust; Sylvia Cho; Mimi Kim; Rebecca P Madan; Esmeralda M Guzman; Margaret Pollack; Julia Epstein; Hillel W Cohen; Marla J Keller; Betsy C Herold
Journal:  Am J Reprod Immunol       Date:  2009-12-15       Impact factor: 3.886

9.  Examining the efficacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing).

Authors:  Devorah R Wieder; Lynn Pattimakiel
Journal:  Int J Womens Health       Date:  2010-11-12

10.  Acceptability of the Nestorone®/ethinyl estradiol contraceptive vaginal ring: development of a model; implications for introduction.

Authors:  Ruth B Merkatz; Marlena Plagianos; Elena Hoskin; Michael Cooney; Paul C Hewett; Barbara S Mensch
Journal:  Contraception       Date:  2014-06-02       Impact factor: 3.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.